Companies › Primus Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 4; Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Metaxalone 640 mg Skeletal muscle relaxant | SLC6A3 | Phase 4 | Sciatica Acute; Healthy Participants | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06157177 | Metaxalone 640 mg | Phase 4 | Sciatica Acute | Other | Nov 2026 |
| NCT07801066 | Metaxalone 640 mg | Phase 4 | Healthy Participants | Other | Jan 2027 |
| NCT07801066 | Metaxalone 640 mg | Phase 4 | Healthy Participants | Other | Jan 2027 |
Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.